


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/26, 9/54, 31/44, 31/41		A1	(11) International Publication Number: WO 99/32093
			(43) International Publication Date: 1 July 1999 (01.07.99)
(21) International Application Number: PCT/SE98/02369			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UJ, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KKE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 17 December 1998 (17.12.98)			
(30) Priority Data: 9704870-6 22 December 1997 (22.12.97) SE			
(71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).			
(72) Inventors; and (75) Inventors/Applicants (for US only): LUNDBERG, Per, Johan [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). SJÖBLOM, Brita [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE).			
(74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S-151 85 Södertälje (SE).			

Published*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: ORAL PHARMACEUTICAL PULSED RELEASE DOSAGE FORM



(57) Abstract

An enteric coated pharmaceutical dosage form comprising a H⁺, K⁺-ATPase inhibitor. The dosage form comprises at least two portions of the H⁺, K⁺-ATPase inhibitor to be released in at least two consecutive pulses. The dosage form has at least one fraction with a pulsed delayed release and another fraction with instant release of the H⁺, K⁺-ATPase inhibitor. The portions are released in time by from 0.5 and up to 12 hours interval, preferably by from 0.5 and up to 8 hours, and more preferably by from 0.5 and up to 4 hours interval. The dosage form is intended for once daily administration.